Brief: Ampio Provides Update On Covid-19 Clinical Trial Activities
19/08/2020 13:50
Aug 19 (Reuters) - Ampio Pharmaceuticals Inc AMPE.A :
* AMPIO PROVIDES UPDATE ON COVID-19 CLINICAL TRIAL
ACTIVITIES
* AMPIO PHARMACEUTICALS INC - FDA REQUESTED COMPREHENSIVE
TESTS ON
SAFETY OF NEBULIZED AMPION AT VARIOUS DOSES
* AMPIO - A CLINICAL TRIAL PROTOCOL FOR TREATING PATIENTS
WHO HAVE
RESPIRATORY DISTRESS DUE TO COVID-19 WITH NEBULIZED AMPION IS
BEING REVIEWED BY FDA
Source text for Eikon: ID:nPn8W30nCa
Further company coverage: AMPE.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ampio Pharmaceuticals
See all newsBrief: Ampio Announces Voluntary Delisting And SEC Deregistration
Brief: Ampio Provides Update On Results From Pre-IND Enabling Studies
Brief: Ampio Selects Ascendia Pharmaceuticals, Inc. To Provide CDMO Services To Support Clinical Development Of OA-201
Brief: Ampio Pharmaceuticals Announces Reverse Stock Split
Brief: Ampio Pharmaceuticals Inc - Holds Approximately $1.25 Million In A Deposit Account At Silicon Valley Bank